Vega Therapeutics Initiates Clinical Trial Program of VGA039 for the Treatment of Von Willebrand Disease
Shots:
-
The first patient has been dosed in the P-I multinational trial evaluating the tolerability, PK, PD & safety of VGA039 after single IV or SC dose administration in healthy patients and single SC dose administration in VWD patients
-
The trial is being conducted following approvals of IND by the US FDA & CTA in the EU. The trial will enroll healthy volunteers & von Willebrand disease patients at clinical trial sites across the US & other countries
-
VGA039 is a first-in-class Ab therapy with a novel mechanism of action that modulates Protein S which showed efficacy in preclinical data in numerous congenital bleeding disorders. VGA039 is also designed to treat additional bleeding disorders, incl. other factor deficiencies & platelet disorders
Ref: Businesswire | Image: Vega Therapeutics
Related News:- Takeda’s Vonvendi Receives the US FDA’s Approval for the Treatment of Severe Type 3 Von Willebrand Disease
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
